Genomic profiling–guided evaluation of metabolic correction with tirzepatide in patients with HFpEF: results from a prospective controlled study in Kazakhstan
The dual GIP/GLP-1 receptor agonist tirzepatide has demonstrated significant metabolic and cardiometabolic benefits in patients with heart failure with preserved ejection fraction (HFpEF). However, molecular mechanisms underlying its cardiovascular effects and determinants of individual therapeutic response remai...